Figure 5
From: Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer’s disease model
Neuropathology is ameliorated by type I and type III NRG1.
Representative immunostaining for MAP2 (A) and presynaptic marker, synaptophysin (B) on sections of the hippocampus of non-Tg and APP- Tg injected with LV-control, LV-NRG1/I or LV-NRG1/III. The area of neuropil occupied by MAP2- or synaptophysin-immunoreactivity was calculated from 9 randomly selected sections per mouse (N = 3) (C). Although MAP2 is primarily a dendritic marker, it can be detected in soma depending on levels of expression. (D) Western blotting analysis of protein extracts of the hippocampus using antibodies against synaptophysin and the postsynaptic marker, PSD95. β-actin was used for a protein loading control. (E) Normalized levels of synaptophysin and PSD95 show a marked increase by LV-NRG1/I and LV-NRG1/III. The results were expressed as mean ± SEM. *p < 0.05. #p < 0.01, denotes a statistically significant difference between Non-Tg/LV-control and Tg/LV-control for the respective markers in panels C and E.
